Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Flutamide-induced late cutaneous pseudoporphyria].

F Mantoux1, P Bahadoran, C Perrin

  • 1Service de Dermatologie, Hôpital L'Archet 2, Nice.

Annales De Dermatologie Et De Venereologie
|June 3, 1999
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Regorafenib as maintenance therapy after first-line doxorubicin-based chemotherapy in advanced non-adipocytic soft tissue sarcomas patients: a double-blind randomised trial.

Annals of oncology : official journal of the European Society for Medical Oncology·2025
Same author

Assessment of the current and emerging criteria for the histopathological classification of lung neuroendocrine tumours in the lungNENomics project.

ESMO open·2024
Same author

Improved nationwide survival of sarcoma patients with a network of reference centers.

Annals of oncology : official journal of the European Society for Medical Oncology·2024
Same author

Sclerosing Epithelioid Fibrosarcoma (SEF) versus Low Grade Fibromyxoid Sarcoma (LGFMS): Presentation and outcome in the nationwide NETSARC+ series of 330 patients over 13 years.

European journal of cancer (Oxford, England : 1990)·2023
Same author

Epithelioid hemangio-endothelioma (EHE) in NETSARC: The nationwide series of 267 patients over 12 years.

European journal of cancer (Oxford, England : 1990)·2023
Same author

Regorafenib in patients with relapsed advanced or metastatic chordoma: results of a non-comparative, randomised, double-blind, placebo-controlled, multicentre phase II study.

ESMO open·2023

This study reports a rare case of pseudoporphyria in a patient treated with flutamide for prostate cancer. Discontinuation of flutamide led to the resolution of skin lesions, highlighting a potential drug-induced side effect.

Area of Science:

  • Dermatology
  • Toxicology
  • Oncology

Background:

  • Pseudoporphyria presents with symptoms similar to porphyria cutanea tarda but without metabolic porphyrin abnormalities.
  • Known causes include hemodialysis, UV exposure, and certain medications like naproxen.
  • Flutamide, an antiandrogen for prostate cancer, is rarely associated with cutaneous side effects.

Observation:

  • A 75-year-old man developed blisters and skin fragility on sun-exposed areas after 1.5 years of flutamide treatment.
  • Histopathology and direct immunofluorescence mimicked porphyria cutanea tarda.
  • Porphyrin metabolism tests were normal.

Findings:

  • Flutamide treatment was identified as the cause of pseudoporphyria.
  • Stopping flutamide resulted in lesion healing and no relapse over 11 months.

Related Experiment Videos

  • This is the third reported case of flutamide-induced cutaneous pseudoporphyria.

    • Implications:

    • Flutamide can induce pseudoporphyria, a rare cutaneous side effect.
    • Physicians should consider flutamide as a potential cause in patients presenting with pseudoporphyria symptoms.
    • Early recognition and drug withdrawal are crucial for managing this condition.